Accessibility Menu
Celldex Therapeutics logo

Celldex Therapeutics

(NASDAQ) CLDX

Current Price$32.41
Market Cap$2.55B
Since IPON/A
5 YearN/A
1 YearN/A
1 MonthN/A

Celldex Therapeutics Financials at a Glance

Market Cap

$2.55B

Revenue (TTM)

$820.00K

Net Income (TTM)

-$283.69M

EPS (TTM)

-$4.27

P/E Ratio

-7.60

Dividend

$0.00

Beta (Volatility)

1.28 (Average)

Price

$32.41

Volume

29,149

Open

$33.96

Previous Close

$32.41

Daily Range

$32.41 - $34.05

52-Week Range

$19.52 - $35.79

Estimated Earnings Date

Aug 6, 2026

CLDX: Motley Fool Moneyball Superscore

51

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Celldex Therapeutics

Industry

Biotechnology

Employees

198

CEO

Anthony S. Marucci, MBA

Headquarters

Hampton, NJ 08827, US

CLDX Financials

Key Financial Metrics (TTM)

Gross Margin

-143%

Operating Margin

-377%

Net Income Margin

-346%

Return on Equity

-49%

Return on Capital

-67%

Return on Assets

-55%

Earnings Yield

-13.16%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.55B

Shares Outstanding

78.49M

Volume

29.15K

Avg. Volume

980.46K

Financials (TTM)

Gross Profit

$1.50M

Operating Income

-$287.40M

EBITDA

-$255.42M

Operating Cash Flow

-$210.95M

Capital Expenditure

-$2.71M

Free Cash Flow

-$213.66M

Cash & ST Invst.

$518.57M

Total Debt

$2.34M

Celldex Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$15.00K

-97.8%

Gross Profit

-$839.00K

+98.4%

Gross Margin

-55.93%

N/A

Market Cap

$2.55B

N/A

Market Cap/Employee

$13.69M

N/A

Employees

186

N/A

Net Income

-$78.69M

-46.3%

EBITDA

-$77.83M

-47.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$451.46M

-32.9%

Total Debt

$1.91M

-44.3%

Accounts Receivable

$230.00K

-78.4%

Inventory

$0.00

N/A

Long Term Debt

$443.00K

-77.0%

Short Term Debt

$1.47M

-2.3%

Return on Assets

-55.49%

N/A

Return on Invested Capital

-67.23%

N/A

Free Cash Flow

-$67.23M

-23.0%

Operating Cash Flow

-$65.59M

-20.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VERAVera Therapeutics, Inc.
$35.09+0.23%
QUREuniQure N.V.
$46.29-3.88%
NUVBNuvation Bio Inc.
$5.56+4.32%
HRMYHarmony Biosciences Holdings, Inc.
$33.28-1.45%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$133.99+0.11%
NOKNokia
$13.49-0.02%
PFEPfizer
$25.21-0.03%
TAT&T
$22.01-0.02%

Questions About CLDX

What is the current price of Celldex Therapeutics?

Celldex Therapeutics is trading at $32.41 per share.

What is the 52-week range for Celldex Therapeutics?

Over the past 52 weeks, Celldex Therapeutics has traded between $19.52 and $35.79.

How much debt does Celldex Therapeutics have?

As of the most recent reporting period, Celldex Therapeutics reported total debt of $1.91M.

How much cash does Celldex Therapeutics have on hand?

Celldex Therapeutics reported $35.73M in cash and cash equivalents in its most recent financial results.

What is Celldex Therapeutics’s dividend yield?

Celldex Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.